About 57% of employer benefits decision-makers think the GLP-1 agonist obesity drugs are a major driver of the increase.

"The vast majority observed that, if the data continued to come in about as expected, it would likely be appropriate to ease policy at the next meeting."

"This doesn't challenge the idea we're still in an expansion, but it does signal we should expect monthly job growth to be more muted and put extra pressure on the Fed to cut rates."

The politicization of ESG debt has eroded the price advantage that issuers enjoyed during the ESG market's boom years.